Emphasizing intuitive workflow and portability, the Universal Wireless Probe reportedly offers a cost-effective combination of phased and linear ultrasound imaging.
Offering the promise of enhanced point-of-care ultrasound (POCUS) imaging in an affordable, portable device, Vave Health has launched the Universal Wireless Probe.
The company said key benefits of the Universal Wireless Probe include:
• high-quality whole-body imaging through a combination of phased and linear imaging capabilities;
• a variety of presets to facilitate ease of use;
• PZT transducer technology; and
• no subscription fees.
In addition to a combination of phased and linear imaging capabilities with the newly launched Universal Wireless Probe ultrasound device, Vave Health said users of the device can also access the VaveCast feature, which enables screen sharing between clinicians. (Image courtesy of Vave Health.)
In addition to a swappable battery to reduce downtime with the Universal Wireless Probe, Vave Health noted that the VaveCast feature, which allows seamless screen sharing with multiple android and IOS devices, facilitates real-time collaboration between clinicians.
"A combination of wireless portability, lack of subscription and membership fees, lifetime software updates, full-body imaging, and rich educational support make the Vave solution the ideal platform for new learners and seasoned POCUS users alike," stated Renee Dversdal, M.D., the chief medical officer at Vave Health.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.